GT Biopharma Regains Nasdaq Minimum Bid Price Compliance
GTBP sits 40% above its 52-week low of $4.91.
Summary
GT Biopharma received Nasdaq confirmation on September 22, 2026 that it has regained compliance with the $1.00 minimum bid price requirement, eliminating the immediate delisting risk.
Key Events · Corporate Governance and Compliance · GTBP
-
Nasdaq Compliance Regained
Nasdaq confirmed on September 22, 2026 that GT Biopharma has regained compliance with the $1.00 minimum bid price requirement after maintaining a closing bid price above $1.00 for at least ten consecutive business days.
-
Delisting Risk Removed
The company had until November 16, 2026 to regain compliance; this confirmation removes the immediate delisting threat that had been hanging over the stock.
-
Reverse Split and Placement Context
Compliance was achieved following the 1-for-25 reverse split effective September 8, 2026 and the $7.75M private placement of Series M convertible preferred stock announced September 21, 2026.
-
Remaining Risks
Despite regaining listing compliance, the company continues to face going concern doubts and an unremediated material weakness in internal controls as disclosed in its August 14, 2026 10-Q.
Analysis · GTBP · Life Sciences
Nasdaq has formally confirmed that GT Biopharma regained compliance with the $1.00 minimum bid price requirement, removing a critical delisting overhang. The company had been under a compliance deadline of November 16, 2026, and this confirmation follows the 1-for-25 reverse split effective September 8 and the recent $7.75M private placement. The stock now trades at $6.89, well above the threshold, but the company still faces going concern doubts and an unremediated material weakness disclosed in its last 10-Q.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 29.3% of the 1512 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GTBP was trading at $6.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.4M. The 52-week trading range was $4.91 to $34.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.